{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T16:57:17Z","timestamp":1794070637420,"version":"4.8.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,24]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy, frequently associated with thrombosis. Immunoglobulin G (IgG) antibodies to heparin-platelet factor 4 (PF4\/H) complexes play a central role in HIT by activating platelets and leukocytes via Fc gamma Receptor IIa (Fc\u03b3RIIA). However, some patients also develop IgG against unmodified PF4 (anti-PF4), but their implication in the pathophysiology of HIT is unclear. Therefore, we assessed the impact of the joint presence of anti-PF4\/H and anti-PF4 antibodies on cellular activation, platelet count, and thrombus formation, using chimeric monoclonal IgG1 antibodies specific for either PF4\/H complexes (5B9) or PF4 alone (1E12). As expected, 5B9 coincubated with washed platelets without heparin did not induce platelet activation, but when a nonactivating concentration of 1E12 was present with 5B9, significant platelet activation was observed. This functional cooperation was Fc dependent and involved Fc\u03b3RIIA receptors, given that it was no longer detectable with F(ab')2 fragments of 1E12 or 5B9 or with ibrutinib, which inhibits the Fc\u03b3RIIA pathway. 5B9 at a nonactivating concentration of 1E12 also induced thrombus formation without heparin under flow conditions. Furthermore, when the 2 antibodies were injected together into human Fc\u03b3RIIA\/human PF4 transgenic mice, thrombocytopenia always occurred, with pulmonary thrombi in one-third of the injected mice, similar to that observed after injection of 5B9 and heparin. These results support that functional cooperation may exist between anti-PF4 antibodies of different specificity and promote cell activation, thrombocytopenia, and thrombosis. This process may also increase the risk of thrombosis in HIT even after heparin treatment has been discontinued.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015095","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T21:01:48Z","timestamp":1742331708000},"page":"3106-3115","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Cooperative effect between anti-PF4\/H and anti-PF4 antibodies increases cell activation and thrombotic risk in HIT"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4718-126X","authenticated-orcid":false,"given":"Sandra","family":"Billy","sequence":"first","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7106-4365","authenticated-orcid":false,"given":"Caroline","family":"Vayne","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"},{"name":"2Centre Hospitalier Universitaire de Tours, Service d\u2019H\u00e9matologie-H\u00e9mostase, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oph\u00e9lie","family":"Bertin","sequence":"additional","affiliation":[{"name":"3INSERM UMR-S 1255, \u00c9tablissement Fran\u00e7ais du Sang Grand Est, Universit\u00e9 de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Miquelestorena-Standley","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"},{"name":"4Centre Hospitalier Universitaire de Tours, Service d'Anatomie et Cytologie Pathologiques, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7948-9763","authenticated-orcid":false,"given":"No\u00e9mie","family":"Charuel","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-9931","authenticated-orcid":false,"given":"Annabelle","family":"Dupont","sequence":"additional","affiliation":[{"name":"5University of Lille, INSERM, Centre Hospitalier Universitaire de Lille, Institut Pasteur de Lille, U1011-EGID, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9533-3320","authenticated-orcid":false,"given":"Lo\u00efs","family":"Co\u00ebnon","sequence":"additional","affiliation":[{"name":"6Universit\u00e9 de Montpellier, INSERM, U1183-IRMB, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3420-8438","authenticated-orcid":false,"given":"Claire","family":"Pouplard","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"},{"name":"2Centre Hospitalier Universitaire de Tours, Service d\u2019H\u00e9matologie-H\u00e9mostase, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotis A.","family":"Senis","sequence":"additional","affiliation":[{"name":"3INSERM UMR-S 1255, \u00c9tablissement Fran\u00e7ais du Sang Grand Est, Universit\u00e9 de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Gruel","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"},{"name":"2Centre Hospitalier Universitaire de Tours, Service d\u2019H\u00e9matologie-H\u00e9mostase, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6861-1551","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Rollin","sequence":"additional","affiliation":[{"name":"1Universit\u00e9 de Tours, INSERM, U1327-ISCHEMIA, Tours, France"},{"name":"2Centre Hospitalier Universitaire de Tours, Service d\u2019H\u00e9matologie-H\u00e9mostase, Tours, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"issue":"7","key":"2025062411215025000_bib1","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0040-1712957","article-title":"Comparative analysis of a French prospective series of 144 patients with heparin-induced thrombocytopenia (FRIGTIH) and the literature","volume":"120","author":"Gruel","year":"2020","journal-title":"Thromb Haemost"},{"issue":"5","key":"2025062411215025000_bib2","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1160\/TH16-02-0109","article-title":"Risk factors for heparin-induced thrombocytopenia: Focus on Fc\u03b3 receptors","volume":"116","author":"Rollin","year":"2016","journal-title":"Thromb Haemost"},{"issue":"2","key":"2025062411215025000_bib3","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1365-2141.1997.4183225.x","article-title":"Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium","volume":"99","author":"Pouplard","year":"1997","journal-title":"Br J Haematol"},{"issue":"11","key":"2025062411215025000_bib4","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1111\/jth.15848","article-title":"Variable serotonin release assay pattern and specificity of PF4-specific antibodies in HIT, and clinical relevance","volume":"20","author":"Rollin","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"26","key":"2025062411215025000_bib5","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1182\/blood.2023022136","article-title":"Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure","volume":"142","author":"Sch\u00f6nborn","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2025062411215025000_bib6","doi-asserted-by":"crossref","first-page":"14945","DOI":"10.1038\/ncomms14945","article-title":"Anti-platelet factor 4\/polyanion antibodies mediate a new mechanism of autoimmunity","volume":"8","author":"Nguyen","year":"2017","journal-title":"Nat Commun"},{"issue":"10","key":"2025062411215025000_bib7","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/jth.13786","article-title":"5B9, a monoclonal antiplatelet factor 4\/heparin IgG with a human Fc fragment that mimics heparin-induced thrombocytopenia antibodies","volume":"15","author":"Kizlik-Masson","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025062411215025000_bib8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1055\/s-0040-1717078","article-title":"Characterization of new monoclonal PF4-specific antibodies as useful tools for studies on typical and autoimmune heparin-induced thrombocytopenia","volume":"121","author":"Vayne","year":"2021","journal-title":"Thromb Haemost"},{"issue":"10","key":"2025062411215025000_bib9","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.3324\/haematol.2021.280251","article-title":"The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies","volume":"107","author":"Vayne","year":"2022","journal-title":"Haematol"},{"issue":"22","key":"2025062411215025000_bib10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.2019000437","article-title":"Cleavage of anti-PF4\/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia","volume":"133","author":"Kizlik-Masson","year":"2019","journal-title":"Blood"},{"issue":"15","key":"2025062411215025000_bib11","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1182\/blood-2014-09-594515","article-title":"Increased risk of thrombosis in Fc\u03b3RIIA 131RR patients with HIT due to defective control of platelet activation by plasma IgG2","volume":"125","author":"Rollin","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2025062411215025000_bib12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/jth.14749","article-title":"Evaluation of functional assays for the diagnosis of heparin induced thrombocytopenia using 5B9, a monoclonal IgG that mimics human antibodies","volume":"18","author":"Vayne","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"8","key":"2025062411215025000_bib13","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.V98.8.2442","article-title":"Heparin-induced thrombocytopenia\/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA","volume":"98","author":"Reilly","year":"2001","journal-title":"Blood"},{"issue":"13","key":"2025062411215025000_bib14","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1182\/blood-2017-08-802769","article-title":"Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice","volume":"132","author":"Hofmann","year":"2018","journal-title":"Blood"},{"issue":"248","key":"2025062411215025000_bib15","doi-asserted-by":"crossref","first-page":"ra78","DOI":"10.1126\/scisignal.2002936","article-title":"Mice lacking the ITIM-containing receptor G6b-B exhibit macrothrombocytopenia and aberrant platelet function","volume":"5","author":"Mazharian","year":"2012","journal-title":"Sci Signal"},{"issue":"5","key":"2025062411215025000_bib16","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.V95.5.1533.005k01_1533_1540","article-title":"Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies","volume":"95","author":"Arepally","year":"2000","journal-title":"Blood"},{"issue":"8","key":"2025062411215025000_bib17","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jtha.2024.05.005","article-title":"The use of 1E12, a monoclonal anti-platelet factor 4 antibody to improve the diagnosis of vaccine-induced immune thrombotic thrombocytopenia","volume":"22","author":"Vayne","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2025062411215025000_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2004-04-1544","article-title":"Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia","volume":"105","author":"Rauova","year":"2005","journal-title":"Blood"},{"issue":"6","key":"2025062411215025000_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1182\/blood-2012-04-424044","article-title":"Polymorphisms of protein tyrosine phosphatase CD148 influence Fc\u03b3RIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia","volume":"120","author":"Rollin","year":"2012","journal-title":"Blood"},{"issue":"9","key":"2025062411215025000_bib20","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1182\/blood-2018-05-850370","article-title":"Fibronectin modulates formation of PF4\/heparin complexes and is a potential factor for reducing risk of developing HIT","volume":"133","author":"Krauel","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2025062411215025000_bib21","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jth.13066","article-title":"Distinguishing between anti\u2013platelet factor 4\/heparin antibodies that can and cannot cause heparin-induced thrombocytopenia","volume":"13","author":"Nazi","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2025062411215025000_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1182\/blood.V91.3.916","article-title":"Antibodies from patients with heparin-induced thrombocytopenia\/thrombosis recognize different epitopes on heparin: platelet factor 4","volume":"91","author":"Suh","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2025062411215025000_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/blood.2021014588","article-title":"Monoclonal and oligoclonal anti-platelet factor 4 antibodies mediate VITT","volume":"140","author":"Kanack","year":"2022","journal-title":"Blood"},{"issue":"9","key":"2025062411215025000_bib24","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood.V92.9.3250","article-title":"Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia","volume":"92","author":"Ziporen","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2025062411215025000_bib25","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1365-2141.2000.02034.x","article-title":"Affinity purification of heparin-dependent antibodies to platelet factor 4 developed in heparin-induced thrombocytopenia: biological characteristics and effects on platelet activation","volume":"109","author":"Amiral","year":"2000","journal-title":"Br J Haematol"},{"issue":"7","key":"2025062411215025000_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.7326\/0003-4819-135-7-200110020-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia and thrombosis","volume":"135","author":"Warkentin","year":"2001","journal-title":"Ann Intern Med"},{"issue":"3","key":"2025062411215025000_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.7326\/0003-4819-136-3-200202050-00009","article-title":"Delayed-onset heparin-induced thrombocytopenia","volume":"136","author":"Rice","year":"2002","journal-title":"Ann Intern Med"},{"issue":"4","key":"2025062411215025000_bib28","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"2025062411215025000_bib29","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2025062411215025000_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1182\/bloodadvances.2022007336","article-title":"Characteristics of VITT antibodies in patients vaccinated with Ad26.COV2.S","volume":"7","author":"Huynh","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2025062411215025000_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa2107051","article-title":"Adjunct immune globulin for vaccine-induced immune thrombotic thrombocytopenia","volume":"385","author":"Bourguignon","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"2025062411215025000_bib32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0042-1758818","article-title":"Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review","volume":"49","author":"Warkentin","year":"2023","journal-title":"Semin Thromb Hemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/12\/3106\/2381748\/blooda_adv-2024-015095-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/12\/3106\/2381748\/blooda_adv-2024-015095-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:22:00Z","timestamp":1750778520000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/12\/3106\/536218\/Cooperative-effect-between-anti-PF4-H-and-anti-PF4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,24]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,6,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015095","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,24]]},"published":{"date-parts":[[2025,6,24]]}}}